Victor, Shaun

Alzheimer’s disease (AD) and Alzheimer’s Related Dementias (ADRD) are projected to affect 50 million people globally in the coming decades. Clinical research suggests that Mild Cognitive Impairment (MCI), a precursor to dementia, offers a critical window of opportunity for lifestyle interventions to delay or prevent the progression of AD/ADRD. Previous research indicates that lifestyle changes, including increased physical exercise, reduced caloric intake, and mentally stimulating activities, can reduce the risk of MCI. Early detection of MCI is challenging due to subtle and often unnoticed cognitive decline and is traditionally monitored through infrequent clinical tests. In this research, the Smart Driving System, a novel, unobtrusive, and economical technology to detect early stages of neurodegenerative diseases, is presented. The system comprises a multi-modal biosensing array (MMS) and AI algorithms, including driving performance and driver’s biometrics, offering insights into a driver’s cognitive function. This publication is the first work reported towards the ultimate goal of developing the Smart Driving Device and App, integrating it into vehicles, and validating its effectiveness in detecting MCI through comprehensive pilot studies.

Ketones are well-known biomarkers of fat oxidation produced in the liver as a result of lipolysis. These biomarkers include acetoacetic acid and β-hydroxybutyric acid in the blood/urine and acetone in our breath and skin. Monitoring ketone production in the body is essential for people who use caloric intake deficit to reduce body weight or use ketogenic diets for wellness or therapeutic treatments. Current methods to monitor ketones include urine dipsticks, capillary blood monitors, and breath analyzers. However, these existing methods have certain disadvantages that preclude them from being used more widely. In this work, we introduce a novel acetone sensor device that can detect acetone levels in breath and overcome the drawbacks of existing sensing approaches. The critical element of the device is a robust sensor with the capability to measure acetone using a complementary metal oxide semiconductor (CMOS) chip and convenient data analysis from a red, green, and blue deconvolution imaging approach. The acetone sensor device demonstrated sensitivity of detection in the micromolar-concentration range, selectivity for detection of acetone in breath, and a lifetime stability of at least one month. The sensor device utility was probed with real tests on breath samples using an established blood ketone reference method.

Energy Expenditure (EE) (kcal/day), a key element to guide obesity treatment, is measured from CO2 production, VCO2 (mL/min), and/or O2 consumption, VO2 (mL/min). Current technologies are limited due to the requirement of wearable facial accessories. A novel system, the Smart Pad, which measures EE via VCO2 from a room’s ambient CO2 concentration transients was evaluated. Resting EE (REE) and exercise VCO2 measurements were recorded using Smart Pad and a reference instrument to study measurement duration’s influence on accuracy. The Smart Pad displayed 90% accuracy (±1 SD) for 14–19 min of REE measurement and for 4.8–7.0 min of exercise, using known room’s air exchange rate. Additionally, the Smart Pad was validated measuring subjects with a wide range of body mass indexes (BMI = 18.8 to 31.4 kg/m2), successfully validating the system accuracy across REE’s measures of ~1200 to ~3000 kcal/day. Furthermore, high correlation between subjects’ VCO2 and λ for CO2 accumulation was observed (p < 0.00001, R = 0.785) in a 14.0 m3 sized room. This finding led to development of a new model for REE measurement from ambient CO2 without λ calibration using a reference instrument. The model correlated in nearly 100% agreement with reference instrument measures (y = 1.06x, R = 0.937) using an independent dataset (N = 56).